

Haematologica
HAEMATOL/2016/152017
Version 4

The Bruton tyrosine kinase inhibitor ibrutinib abrogates triggering
receptor on myeloid cells 1 mediated neutrophil activation

Nicole Stadler, Astrid Hasibeder, Pamela Aranda Lopez, Daniel
Teschner, Alexander Desuki, Oliver Kriege, Alexander N. R. Weber,
Christoph Schulz, Christian Michel, Georg Heß, and Markus P. Radsak

Disclosures: This manuscript contains in part data of the medical doctoral thesis of NS. This work was supported by the University Medical Center Mainz („Forschungszentrum Immuntherapie“; intramural funding to CM), Deutsche Forschungsgemeinschaft (TRR156/1 A05 to MPR), Deutsche Gesellschaft für Innere Medizin (fellowship to NS). All authors declare no conflicts of interest with the submitted manuscript.

Contributions: NS, CM, DT performed the experiments. AH prepared the figures and contributed to writing the manuscript. GH, AD, OK, CS contributed lymphoma patients PAL reviewed the data, prepared the figures and contributed to writing the manuscript. AW contributed to the design of the study. MPR designed the research and wrote the manuscript.